Literature DB >> 12237266

A prospective epidemiologic survey on the prevalence of foot disease in Hong Kong.

Michael Kam Tim Chan1, Lai-Yin Chong.   

Abstract

A prospective epidemiologic survey on the prevalence of foot disease in Hong Kong found foot disease in 64% of patients screened. All of the patients were ethnically Chinese. Of the conditions specified in the questionnaire, fungal foot infection, tinea pedis, and toenail onychomycosis were the most frequently encountered conditions, followed by metatarsal corns, eczema, psoriasis, and pes planus. Vascular disease, osteoarticular pathology, diabetes mellitus, obesity, atopy, and participation in sports were the main factors coexisting with the foot conditions. Of the study population, 17% and 21% reported that their quality of life was affected by pain and discomfort, respectively. These percentages are much lower than those obtained in other studies; it may therefore be inferred that foot complaints are being neglected by the ethnic Chinese population in Hong Kong.

Entities:  

Mesh:

Year:  2002        PMID: 12237266     DOI: 10.7547/87507315-92-8-450

Source DB:  PubMed          Journal:  J Am Podiatr Med Assoc        ISSN: 1930-8264


  3 in total

Review 1.  Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy.

Authors:  Boni E Elewski; Antonella Tosti
Journal:  J Clin Aesthet Dermatol       Date:  2015-11

2.  Psychosocial perception of adults with onychomycosis: a blinded, controlled comparison of 1,017 adult Hong Kong residents with or without onychomycosis.

Authors:  Henry Hl Chan; Emma T Wong; Chi Keung Yeung
Journal:  Biopsychosoc Med       Date:  2014-07-15

3.  Antifungal mode of action of macrocarpal C extracted from Eucalyptus globulus Labill (Lan An) towards the dermatophyte Trichophyton mentagrophytes.

Authors:  Jack Ho Wong; Kit-Man Lau; Yu-On Wu; Ling Cheng; Chun-Wai Wong; David Tai-Wai Yew; Ping-Chung Leung; Kwok-Pui Fung; Mamie Hui; Tzi-Bun Ng; Clara Bik-San Lau
Journal:  Chin Med       Date:  2015-11-21       Impact factor: 5.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.